Optic Neuritis  >>  opicinumab (BIIB033)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
opicinumab (BIIB033) / Biogen
RENEW, NCT01721161 / 2011-006291-39: BIIB033 In Acute Optic Neuritis (AON)

Completed
2
82
Canada, Europe, RoW
BIIB033 (anti-LINGO-1 mAb), anti-LINGO-1 monoclonal antibody (mAb), Opicinumab, Placebo
Biogen
Acute Optic Neuritis
10/14
10/14

Download Options